The Pharmacology Core's mission is to provide state-of-the-art technology and expertise in bioanalysis, pharmacokinetics, and pharmacogenetics for evaluation of critical pharmacological endpoints in preclinical and eariy phase clinical studies. Two services, including pharmacokinetic/pharmacodynamic (PK/PD) sample processing and distribution service and bioanalysis service, have been provided since 2004. The PK/PD sample processing and distribution service provides support for clinical trials, including specimen transport, accountability, processing, storage, and distribution, in compliance with applicable Standard Operating Procedures (SOPs), IRB-approved protocols, and regulatory requirements. The bioanalysis service provides quantitative measurement of drugs and metabolites in biological samples (e.g., blood, plasma, serum, urine, or tissue samples) using high-performance liquid chromatography (HPLC) coupled with ultraviolet or fluorescence detection or tandem mass spectrometer detection (LC-MS/MS). In addition, three new service lines were recently developed in order to provide KCI investigators with comprehensive pharmacology support. These new services include: 1) bioanalytical methods development and validation service that includes evaluating all procedures for accuracy, precision, selectivity, sensitivity, reproducibility and stability of a particular HPLC or LC-MS/MS method;2) pharmacokinetic data analysis and modeling service that provides assistance in preclinical and clinical pharmacokinetic experimental design and protocol development as well as analysis and interpretation of pharmacokinetic data using traditional or population pharmacokinetic modeling approaches;and 3) pharmacogenetic analysis is a collaborative service with the Genomics Core that focuses on employing a candidate gene approach to examine the associations between common single nucleotide polymorphisms (SNPs) in selected genes (such as genes encoding drug metabolizing enzymes, transporters, or target receptors/enzymes) and PK parameters, PD effects, or clinical outcome (efficacy or toxicity) of clinical investigational anticancer agents. The Core is equipped with stateof- the-art analytical instruments such as LC-MS/MS. Available pharmacokinetic analysis software includes WinNonlin version 5.2 and NONMEM version 6. The laboratory is centrally located with convenient access forthe KCI investigators.
The Pharmacology Core provides a centralized unit to facilitate cancer related clinical, translational, and basic science research with evaluation of critical pharmacological endpoints. The availability of this facility minimizes the cost and efforts of KCI investigators, and fosters interdisciplinary collaborations.
|Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26|
|Bonomi, Robin; Popov, Vadim; Laws, Maxwell T et al. (2018) Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [18F]-2-Fluorobenzoylaminohexanoicanilide. J Med Chem 61:7116-7130|
|Paximadis, Peter; Beebe-Dimmer, Jennifer L; George, Julie et al. (2018) Comparing Treatment Strategies for Stage I Small-cell lung Cancer. Clin Lung Cancer 19:e559-e565|
|Modi, Dipenkumar; Al-Kadhimi, Zaid; Chen, Wei et al. (2018) A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation. Am J Hematol 93:E96-E98|
|Patki, Mugdha; McFall, Thomas; Rosati, Rayna et al. (2018) Chronic p27Kip1 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. Sci Rep 8:16006|
|Teslow, Emily A; Bao, Bin; Dyson, Greg et al. (2018) Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol Oncol 12:1138-1152|
|Rathinam, Rajamani; Rosati, Rita; Jamesdaniel, Samson (2018) CRISPR/Cas9-mediated knockout of Lim-domain only four retards organ of Corti cell growth. J Cell Biochem 119:3545-3553|
|Munkanatta Godage, Dhanushka N P; VanHecke, Garrett C; Samarasinghe, Kusal T G et al. (2018) SMYD2 glutathionylation contributes to degradation of sarcomeric proteins. Nat Commun 9:4341|
|Han, Jing; Li, Yue; Liu, Xiuli et al. (2018) Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS One 13:e0193031|
|McKnight, Brooke N; Kuda-Wedagedara, Akhila N W; Sevak, Kuntal K et al. (2018) Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep 8:9043|
Showing the most recent 10 out of 826 publications